Background: Human papillomavirus (HPV) testing from clinician-collected cervical and self-collected cervico-vaginal samples is more sensitive for detecting CIN2
Introduction
Human papillomavirus (HPV) testing has very high sensitivity for detecting cervical cancer precursor lesions defined as cervical intraepithelial neoplasia grade 2 (CIN2), grade 3 (CIN3) or adenocarcinoma in situ (AIS). Sensitivity for CIN3 or AIS is typically above 95% for a range of well-characterized tests (1, 2) .
However, a major impediment to controlling cervical cancer is lack of attendance for screening. In the United Kingdom, United States, and other developed countries, failure to be screened in the past 5 years, or never having been screened, occurs in at least 20% to 30% of women of screening age (3, 4) . More than half of all cervical cancers are found in this subgroup (5, 6) . Screening attendance is substantially lower in those countries without well-developed screening programs where from 50% to more than 80% of women are not screened (7) . Previous studies indicate that HPV testing from liquid-based clinician-collected cervical samples and self-collected cervico-vaginal samples is more sensitive for detecting CIN2 þ /CIN3 þ than cytology-based screening, and offering self-sampling may improve the uptake of screening (8, 9) . A recent meta-analysis of 14 studies evaluated the use of urine samples for HPV testing and reported a pooled sensitivity of 77% and specificity of 88% for high-risk HPV (HR-HPV) compared with HR-HPV from the cervix (10) . However, there was substantial heterogeneity between the studies in terms of HPV test used, other methodology, and disease outcome. Importantly, in these studies, no association between HPV test positivity and CIN2 þ or CIN3 þ was reported, and therefore, the clinical sensitivity for detecting cervical cancer precursor lesions with urine-based HPV testing remained unknown. Burroni and colleagues (2015) 
Materials and Methods

Population
This work was a substudy of the PreservCyt versus SurePath: PREDICTORS 4 prospective study among women with abnormal cytology newly referred to the St Mary's Hospital colposcopy clinic (London, United Kingdom) between September 14, 2011, and April 26, 2013. All women were sent a patient information sheet with their appointment letter giving full details of the study and assuring them that their care would not be affected if they chose not to participate. Women were eligible if referred as a result of one or more abnormal cervical cytology screening results with the most recent being within 3 months of their colposcopy visit, were not pregnant, had not been treated previously for CIN, nor had a hysterectomy. Participants were recruited by convenience sampling with no selection but based on staff availability and not interfering with the patient waiting times. All women provided written informed consent.
Sample collection methods
Prior to colposcopy and biopsy, women were asked whether they would provide a urine sample for HPV testing. The participant was asked not to wipe the labia before urinating and to provide 40 to 100 mL of urine. A proprietary preservative solution was added to the urine sample within 10 minutes by clinic staff. Women were also asked to consent to their clinician collecting two cervical cytology samples with Cervex brushes (Rovers Medical Devices B.V.) for research purposes at the start of their colposcopy examination. One brush sample was placed in a ThinPrep vial containing 20 mL PreservCyt Solution and the other went into a vial containing 10 mL of SurePath Preservative Fluid (BD Diagnostics). The order of cervical sampling was randomized to eliminate potential bias associated with sampling order. Only the urine sample and a 1-mL aliquot of the PreservCyt cervical sample were used for Trovagene HPV testing for this substudy.
Data collection and blinding
All samples were pseudoanonymized and identifiable only by participant number. Study results were used for research purposes only. Participants were made aware prior to consent that they would not be informed of their test results. Pseudoanonymized aliquots, blind to all other information, were shipped at ambient temperature to the Trovagene laboratory in San Diego, CA, where the HPV testing was performed. Results were then sent to the Centre for Cancer Prevention in London, United Kingdom, where data entry and all analyses were performed according to a predefined statistical analysis plan. All pathology results were centrally reviewed by an external, independent expert pathologist (M.H. Stoler), who was blinded to all data and whose histologic diagnosis was used for analyses. Worst histology was defined as the highest grade of histology, whether diagnostic punch biopsy or excision biopsy collected at baseline or within 9 months.
HPV assay details
For the Trovagene HPV test, DNA was extracted from 0.5 mL of the urine sample using the QIAamp MinElute Virus Vacuum Kit (Qiagen) according to the manufacturer's instructions. Cells from a 1-mL aliquot of the PreservCyt cervical sample were pelleted, washed with PBS, and then DNA was extracted with the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's instructions. Isolated DNA from both urine and PreservCyt samples (5 mL) was tested with the Trovagene HPV test (Trovagene Inc.), a PCR test that amplifies a region in the E1 gene of 13 HR-HPV genotypes (16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59, and 68) and provides a consensus positivity result. The assay also detects the RNaseP gene as a control.
The PCR product was subjected to capillary electrophoresis for fragment size analysis on the ABI 3130 instrument (Thermo Fisher Scientific), and results were reported as HR-HPV positive or negative based on the presence of a 92-96 bp fragment above a predefined threshold (500 RFU). The 95% detection limit for most of the 13 HR-HPV types is 100 copies, with some types (HPV 39 and HPV 51) higher (1,000 or more copies). Crossreactivity was observed with HPV types 30, 53, 67, and 70, but not with HPV 6, 11, 26, 34, 69, and 82 (data on file).
Disease assessment
Histopathology, reviewed by a single well-recognized external expert (M.H. Stoler), was used as the reference standard to determine disease status. Histopathologically diagnosed high-grade CIN (CIN2 þ cancer. The pathologist was blinded to all HPV results and clinical information. The three laboratory personnel conducting the Trovagene HPV testing were based in the manufacturer's laboratory, had extensive experience with the assay, and were also blinded to the disease status of the women and all other HPV results.
Statistical analysis
Sensitivity and specificity (with 95% CIs) were used to describe the test performance, and comparisons between samples were made using a simple binomial agreement test and McNemar test for discordant pairs, both overall and within the CIN3
and <CIN2 groups. A sample size of 500 women was chosen to give a 95% CI of (0.84-0.94) for sensitivity for CIN2 þ , assuming that its true value was 90% and prevalence was 30%, based on previous PREDICTORS studies.
Ethical approval
This study received ethical approval on August 2, 2011, from NHS Health Research Ethics Service, NRES Committee LondonHampstead (reference 11/LO/1147).
Results
A flow diagram for the study is shown in Fig. 1 . A total of 652 women agreed to have two cervical cytology specimens taken, one PreservCyt and one SurePath, and of these, 564 also consented to provide a urine sample. Of these, 20 were excluded after enrolment for the following reasons: not meeting the referral criteria (9), incomplete consent forms (3), having no biopsy taken despite an abnormal colposcopy (5), or due to deviation from study procedures (3). In addition, 26 urine samples were excluded before transportation to Trovagene because of insufficient volume þ . The HPV positivity rate with the Trovagene HPV test was 80% (403/501) for the cervical samples and 79% (396/501) for the urine samples, which was the same when using all urine samples, including those not matched to cervical samples (408/518). There was no difference in HPV positivity when the PreservCyt was the first or second cervical sample [80% when PreservCyt was the first sample (199/250) vs. 81% when it was the second sample (204/ 251)]. There were 47 HPV-positive cervical samples that were urine negative and 40 HPV-positive urine samples that were negative for the cervical sample (Table 2; Fig. 1 ), yielding an agreement between the samples of 82.6% (95% CI, 79.3-86.0), a kappa of 0.46 (95% CI, 0.37-0.56), and a McNemar OR for discordant pairs of 0.85 (95% CI, 0.54-1.33; P ¼ 0.52). Using the PapType full typing test (Genera Biosystems), multiple HPV types were found in 108 samples. Positivity was four times more common in the cervical samples than urine (86 vs. 22). In no case was discordance by HPV type significantly different in the two sample types, although numbers were small. There was no statistically significant difference in positivity by age (data not shown).
As shown in 
Discussion
These results indicate that the Trovagene HPV test performs similarly to other sensitive HPV tests for PreservCyt cervical samples and is only slightly, but not significantly, less sensitive and equally specific for urine samples. The very high sensitivity in cervical samples suggests that the lower sensitivity in urine is due to specimen type differences and not the assay itself. Similar findings, that is, lower sensitivity with urine compared with cervical samples, for an HPV genotyping test have been reported elsewhere. In that study (15) , Linear Array HPV Genotyping Test (LA-HPV; Roche Molecular Systems) was used for evaluating both urine and cervical samples, with a greater difference in sensitivity for CIN2 þ between the sample types (urine 80.8% vs. cervical 96.2%). A prototype of the Trovagene HPV test yielded 92.3% sensitivity for CIN2/3 in urine samples (15) . The current study is the first to evaluate Trovagene HPV test using paired urine and Table 2 . HPV test positivity in PreservCyt cervical and urine samples overall and according to histology result with number of discordant pairs, percent agreement, and McNemar OR for discordant pairs
Population Total
Positive cervix % (95% CI) NOTE: Column with þ/À denotes cases positive for cervix and negative for urine and vice versa for À/þ. a cervical samples from the same woman. We found the sensitivity observed for urine in this study to be comparable with cytology in our previous referral population study conducted in the same clinic, where a sensitivity of cytology for CIN2 þ of 88.9% (95% CI, 85.1-91.9) was observed (2). The low specificity is also representative of results found for other tests in a referral population (2) . Testing urine for sexually transmitted infections is widely performed and accepted by both men and women. Such testing requires first catch (initial stream of 20-50 mL) from a void at any time of day (16) . It has been suggested that the accuracy of HPV testing from urine samples might be improved if the initial stream specimen was used to increase HPV DNA concentration, or a DNA conservation buffer. In our study, we sent an average of 55 mL (minimum 20 mL) of urine for testing, but did not specifically collect first catch (initial stream) or clean catch (midstream) urine that is collected for the detection of sexually transmitted infections and urinary tract infections, respectively. This was based on a small pilot urine sampling study using a morning void urine sample, and initial stream and midstream samples from urine samples collected at the clinic. Urine samples were tested using the Trovagene HPV test, and all samples showed the same sensitivity for CIN2 þ (0.88; 95% CI, 0.56-0.99) and specificity appeared comparable, suggesting that the results may be less dependent on the timing and urine stream of the sample collection (17) . Within our reported study, samples were collected at the clinic, at any time of the day, with a preservative manually added immediately after collection to maintain the integrity of the sample; however, tubes precoated with a preservative would be better suited for selfcollection. Additional research is needed to identify optimal urine sample collection parameters and to improve the preservative delivery process. In our study, women were not surveyed to assess the acceptability and preference for physician-collected cervical samples versus self-collected urine samples. However, in the pilot urine sampling study, when surveyed, women preferred self-sampling over physician-sampling and specifically urine sampling over selfcollected cervico-vaginal samples (17) . The sample size of that study was small, and thus, more work also should be done to understand whether women prefer to provide a self-collected vaginal sample or a urine sample and to understand whether there are cultural differences in different populations.
Lack of compliance remains the limiting feature in cervical screening. In the long term, vaccination against HPV infection in early adolescence will help to address the problem of lack of screening, but this does not help women who are now over the age of 25 years, where screening remains the primary preventive measure (18) (19) (20) (21) . Self-sampling is an important addition to cervical screening, enabling samples for HPV testing to be Table 3 . Agreement between the Trovagene HPV test and other HPV tests using the PreservCyt cervical sample obtained from unscreened or underscreened women. Most studies have been conducted on self-collected cervico-vaginal samples, but urine may prove to be a more acceptable sample for many women. Previous studies have shown that a referral population is usually an efficient and accurate measure of sensitivity in a screening context, but its higher HPV positivity rate may make it is less reliable for assessing the specificity (2, 22) . This was not however seen by C ombita and colleagues, who found overall HPV prevalence in paired urine and cervical samples from unvaccinated 18 to 25 year olds attending for screening was 64.7% and 60.0%, respectively (23). This does not support the common view that HPV prevalence is lower in urine. Further studies are needed to validate the performance of the Trovagene HPV test with urine sampling, especially for specificity in a screening population. This should potentially include self-samples, although a previous study in a UK screening population comparing self-samples and clinician samples showed no statistically significant difference in sensitivity for CIN2 þ (19% difference; 95% CI, 0.2-40) and only a marginally significant difference in specificity (2% difference; 95% CI, 0.3-4; ref. 24 ).
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